Table 1

Distribution of diagnoses in the anti-SSA and/or anti-SSB positive population according to the fine reactivity defined by line immunoassay

nSLE % (95% CI)CLE % (95% CI)SCl % (95% CI)RA % (95% CI)PM/DM % (95% CI)pSS % (95% CI)Other % (95% CI)
CLE, cutaneous lupus without systemic involvement; ID, immunodiffusion; PM/DM, polymyositis/dermatomyositis; pSS, primary Sjögren's syndrome;. RA, rheumatoid arthritis; SCl, scleroderma; SLE, systemic lupus erythematosus.
SSA+ and/or SSB+18145.3 (47.1 to 62.1)7.7 (4.3 to 12.6)8.8 (5.1 to 14.0)7.7 (4.3 to 12.6)2.2 (0.6 to 5.6)14.4 (9.6 to 20.3)13.8 (9.1 to 19.7)
Line immunoassay result:
Ro52+Ro60−SSB−3815.8 (6 .0 to 31.3)2.6 (0.07 to 13.8)34.2 (19.6 to 51.4)7.9 (1.7 to 21.4)10.5 (2.9 to 24.8)7.9 (1.7 to 21.4)21.1 (9.6 to 37.2)
Ro52−Ro60+SSB−1080.0 (44.4 to 97.5)010.0 (0.03 to 44.5)00010.0 (0.03 to 44.5)
Ro52−Ro60−SSB+1040.0 (12.2 to 73.8)20.0 (2.5 to 55.6)10.0 (0.03 to 44.5)20.0 (2.5 to 55.6)0010.0 (0.03 to 44.5)
Ro52+Ro60+SSB−2352.2 (30.6 to 73.2)8.7 (1.1 to 28.4)08.7 (1.1 to 28.4)017.4 (4.95 to 38.8)13.0 (2.8 to 33.6)
Ro52+Ro60−SSB+333.3 (0.8 to 90.6)66.7 (9.4 to 99.2)00000
Ro52−Ro60+SSB+922.2 (2.8 to 60.0)22.2 (2.8 to 60.0)022.2 (2.8 to 60.0)011.1 (0.3 to 48.3)22.2 (2.8 to 60.0)
Ro52+Ro60+SSB+8655.8 (44.7 to 66.5)5.8 (1.9 to 13.1)1.2 (0.03 to 6.3)5.8 (1.9 to 13.1)020.9 (12.9 to 31.1)10.5 (4.9 to 18.9)
Ro52−Ro60−SSB−250.0 (1.3 to 98.7)0000050.0 (1.3 to 98.7)
ID+